PIGA GERMLINE MUTATIONS CAUSE DECREASED HEPCIDIN EXPRESSION AND A NOVEL SUBTYPE OF HEREDITARY HEMOCHROMATOSIS

EHA Library, Oriana Marques, 324508

THE BEYOND STUDY: RESULTS OF A PHASE 2, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED MULTICENTER STUDY OF LUSPATERCEPT IN ADULT PATIENTS WITH NON-TRANSFUSION DEPENDENT BETA-THALASSEMIA

EHA Library, Ali Taher, 324509

HEMATOPOIETIC STEM CELL-GENE THERAPY FOR MUCOPOLYSACCHARIDOSIS TYPE I, HURLER: EVIDENCE OF EXTENSIVE METABOLIC CORRECTION AND EARLY CLINICAL RESPONSE

EHA Library, Maria Ester Bernardo, 324510

PAZOPANIB FOR SEVERE BLEEDING AND TRANSFUSION-DEPENDENT ANEMIA IN HEREDITARY HEMORRHAGIC TELANGIECTASIA

EHA Library, Hanny Al-Samkari, 324511

A Β2 ADRENERGIC RECEPTOR AGONIST CORRECTS DYSREGULATED POLARIZATION OF T HELPER CELLS IN PRIMARY IMMUNE THROMBOCYTOPENIA

EHA Library, Xiao-Hui Zhang, 324512

DYSREGULATION OF CHROMATIN MODIFIERS DRIVES LINEAGE SWITCH IN MLL-R ACUTE LEUKEMIA

EHA Library, Katarzyna Szoltysek, 324513

IL7R MUTATIONAL ACTIVATION CAN INITIATE PH-LIKE AND PAX5 P80R PRECURSOR B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA

EHA Library, Joao Barata, 324514

BRUTON’S TYROSINE KINASE INHIBITION SENSITIZES ACUTE LYMPHOBLASTIC LEUKEMIA TO ASPARAGINASE BY INTERFERING WITH THE AMINO ACID RESPONSE - A ROLE FOR C-MYC

EHA Library, Miriam Butler, 324515

EHMT2/G9A DRIVES THE EPIGENETIC REGULATION OF GLUCOSE METABOLISM IN T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA

EHA Library, Anna Montanaro, 324516

INDUCIBLE RNA INTERFERENCE IN PATIENTS´ ACUTE LEUKEMIA PDX MODELS IN VIVO TO IDENTIFY AND VALIDATE THERAPEUTIC TARGETS

EHA Library, Michela Carlet, 324517

LOSS OF IKZF1 CONTRIBUTES TO CYTARABINE RESISTANCE IN B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA

EHA Library, Britt Vervoort, 324518

REDEFINING LOW RISK HIGH HYPERDIPLOIDY IN PAEDIATRIC ACUTE LYMPHOBLASTIC LEUKAEMIA

EHA Library, Anthony Moorman, 324519

UPDATED RESULTS OF THE GIMEMA LAL2116, D-ALBA TRIAL, FOR NEWLY DIAGNOSED ADULTS WITH PH+ ALL

EHA Library, Sabina Chiaretti, 324520

INTERIM RESULTS OF A PHASE II STUDY OF BLINATUMOMAB PLUS PONATINIB FOR PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA

EHA Library, Nicholas Short, 324521

PRELIMINARY RESULTS OF THE GIMEMA LAL2317 SEQUENTIAL CHEMOTHERAPY-BLINATUMOMAB FRONT-LINE TRIAL FOR NEWLY DIAGNOSED ADULT PH-NEGATIVE B-LINEAGE ALL PATIENTS

EHA Library, Renato Bassan, 324522

DONOR-DERIVED CD7 CAR T CELLS FOR T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA

EHA Library, Jing Pan, 324523

OUTCOMES OF CHILDREN AGED UNDER 3 YEARS TREATED WITH TISAGENLECLEUCEL FOR B-ALL

EHA Library, Sara Ghorashian, 324524

PHASE 2 RESULTS OF THE ZUMA-3 STUDY EVALUATING KTE-X19, AN ANTI-CD19 CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY, IN ADULT PATIENTS WITH RELAPSED/REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA

EHA Library, Gunjan Shah, 324525

A NOVEL CD19/CD20 DUAL SYNTHETIC T-CELL RECEPTOR AND ANTIGEN RECEPTOR (STAR) T CELL THERAPY FOR REFRACTORY AND RELAPSED (R/R) B CELL ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL)

EHA Library, Peihua Lu, 324526

LONG-TERM FOLLOW-UP OF SEQUENTIAL CD19-22 CAR T-CELL THERAY IN 20 CHILDREN WITH REFRACTORY OR RELAPSED B-ALL

EHA Library, Kaiting Tang, 324527

NONCODING REGULATORY LOCUS MYNRL15 MODULATES CHROMATIN ARCHITECTURE AND REPRESENTS A NOVEL MYELOID LEUKEMIA DEPENDENCY

EHA Library, Michelle Ng, 324528

HUMAN ENDOGENOUS RETROVIRUSES CHARACTERIZE THE DIFFERENT SUBPOPULATIONS OF NORMAL AND LEUKEMIC CELLS AND REPRESENT A SOURCE OF EPITOPES FOR CANCER IMMUNOTHERAPY IN ACUTE MYELOID LEUKEMIA

EHA Library, Vincent Alcazer, 324529

ISOFORM-SPECIFIC AND SIGNALING-DEPENDENT PROPAGATION OF ACUTE MYELOID LEUKEMIA BY WILMS TUMOR 1

EHA Library, Constanze Bonifer, 324530

MYC SUPER-ENHANCER HIJACKING BY EVI1 IN LEUKEMIA IS CTCF DEPENDENT

EHA Library, Roger Mulet Lazaro, 324531

TET3 PROMOTES GROWTH AND EPIGENETICALLY REGULATES GLUCOSE METABOLISM AND LEUKEMIC STEM CELL ASSOCIATED PATHWAYS IN ACUTE MYELOID LEUKEMIA

EHA Library, Shiva Bamezai, 324532

RELEASE OF INTERFERON-GAMMA BY AML CELLS REMODELS BONE MARROW IMMUNE MICROENVIRONMENT BY INDUCING REGULATORY T CELLS

EHA Library, Marilena Ciciarello, 324533

INHIBITION OF CYSTINE IMPORT BY REPURPOSING OF SULFASALAZINE TO TREAT ACUTE MYELOID LEUKEMIA

EHA Library, Raphael Itzykson, 324534

FUNCTIONAL IN VIVO CHARACTERISTICS OF PDX AML SINGLE CELL CLONES PREDICT OUTCOME IN LARGE AML PATIENT COHORTS

EHA Library, Binje Vick, 324535

STANDARDIZING NGS-MRD IN AML: AN INTERNATIONAL STUDY BY THE ELN-MRD WORKING PARTY

EHA Library, Michael Heuser, 324536

ACUTE RESISTANCE TO BET INHIBITORS REMODELS COMPENSATORY TRANSCRIPTIONAL PROGRAMMES VIA P300 CO-ACTIVATION

EHA Library, Daniel Sasca, 324537

SEQUENTIAL NCRI AML TRIALS SHOW CONSISTENT BENEFIT FOR RIC TRANSPLANT IN CR1 FOR OLDER PATIENTS >60YEARS THAT IS INDEPENDENT OF MRD STATUS AFTER FIRST INDUCTION

EHA Library, Nigel Russell, 324538

SURVIVAL OUTCOMES FROM THE QUAZAR AML-001 TRIAL WITH ORAL AZACITIDINE FOR PATIENTS WITH ACUTE MYELOID LEUKEMIA IN REMISSION BY DISEASE SUBTYPE, CYTOGENETIC RISK, AND NPM1 MUTATION STATUS AT DIAGNOSIS

EHA Library, Hartmut Döhner, 324539

RUNX1 MUTATIONS IN NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA DO NOT ADVERSELY IMPACT CLINICAL OUTCOMES IN THE MODERN ERA

EHA Library, Sangeetha Venugopal, 324540

A UNIFIED CLASSIFICATION AND RISK STRATIFICATION ALGORITHM TO SUPPORT CLINICAL DECISIONS IN ACUTE MYELOID LEUKEMIA

EHA Library, Elli Papaemmanouil, 324541

A NATIONAL DANISH PROOF OF CONCEPT ON FEASIBILITY AND SAFETY OF HOME -BASED INTENSIVE CHEMOTHERAPY IN PATIENTS WITH ACUTE MYELOID LEUKEMIA

EHA Library, Kristina Nørskov, 324542

EFFICACY AND SAFETY OF VENETOCLAX IN COMBINATION WITH GILTERITINIB FOR RELAPSED/REFRACTORY FLT3-MUTATED ACUTE MYELOID LEUKEMIA: UPDATED ANALYSES OF A PHASE 1B STUDY

EHA Library, Jessica K. Altman, 324543

A PHASE IB/II STUDY OF IVOSIDENIB WITH VENETOCLAX +/- AZACITIDINE IN IDH1-MUTATED MYELOID MALIGNANCIES

EHA Library, Curtis Lachowiez, 324544

MEASURABLE RESIDUAL DISEASE RESPONSE IN ACUTE MYELOID LEUKEMIA TREATED WITH VENETOCLAX AND AZACITIDINE

EHA Library, Keith Pratz, 324545

EFFECT OF OLUTASIDENIB (FT-2102) ON COMPLETE REMISSIONS IN PATIENTS WITH RELAPSED/REFRACTORY MUTANT IDH1 ACUTE MYELOID LEUKEMIA. RESULTS FROM A PLANNED INTERIM ANALYSIS OF A PHASE 2 CLINICAL TRIAL

EHA Library, Stéphane De Botton, 324546

FLAVIDA CHEMOTHERAPY INDUCES MRD-NEGATIVE REMISSION IN PATIENTS WITH RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA

EHA Library, Rabia Shahswar, 324547

CANCER STEMNESS ASSOCIATES WITH HIGH EXPRESSION LEVEL OF ROR1 AND VENETOCLAX RESISTANCE IN CHRONIC LYMPHOCYTIC LEUKEMIA

EHA Library, Emanuela M. Ghia, 324548

SKEWED PRIMARY ANTIGEN-SPECIFIC RESPONSES AND CHROMATIN REMODELING OF T CELLS IN A COMBINED OT-I/TCL-1 ADOPTIVE TRANSFER MODEL

EHA Library, Fleur S. Peters, 324549

FOXO1-GAB1 AXIS REGULATES HOMING CAPACITY AND TONIC AKT ACTIVITY IN CHRONIC LYMPHOCYTIC LEUKEMIA: NOVEL THERAPEUTIC TARGET

EHA Library, Vaclav Seda, 324550

CLINICAL IMPACT OF RECURRENT GENE MUTATIONS IN CHRONIC LYMPHOCYTIC LEUKEMIA: A RETROSPECTIVE, MULTI-CENTER COHORT STUDY BY ERIC, THE EUROPEAN RESEARCH INITIATIVE ON CLL, IN HARMONY

EHA Library, Larry Mansouri, 324551

GENETIC MARKERS AND OUTCOME IN FRONT LINE OBINUTUZUMAB PLUS CHLORAMBUCIL OR VENETOCLAX - UPDATED ANALYSIS OF THE CLL14 TRIAL

EHA Library, Eugen Tausch, 324552

FIRST RESULTS OF A HEAD-TO-HEAD TRIAL OF ACALABRUTINIB VERSUS IBRUTINIB IN PREVIOUSLY TREATED CHRONIC LYMPHOCYTIC LEUKEMIA

EHA Library, Peter Hillmen, 324553

VENETOCLAX-OBINUTUZUMAB FOR PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA: 4-YEAR FOLLOW-UP ANALYSIS OF THE RANDOMIZED CLL14 STUDY

EHA Library, Othman Al-Sawaf, 324554

PRIMARY ANALYSIS OF THE FIXED-DURATION COHORT FROM THE PHASE 2 CAPTIVATE STUDY OF FIRST-LINE IBRUTINIB + VENETOCLAX FOR CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA

EHA Library, John N. Allan, 324555

ACALABRUTINIB ± OBINUTUZUMAB VS OBINUTUZUMAB + CHLORAMBUCIL IN TREATMENT-NAÏVE CHRONIC LYMPHOCYTIC LEUKEMIA: ELEVATE-TN 4-YEAR FOLLOW-UP

EHA Library, Jeff P. Sharman, 324556

MRD-GUIDED OR FIXED 12 CYCLES OF VENETOCLAX CONSOLIDATION AFTER VENETOCLAX PLUS OBINUTUZUMAB TREATMENT IN FIRST-LINE FCR UNFIT PATIENTS WITH CLL: PRIMARY ENDPOINT ANALYSIS OF THE HOVON 139/GIVE TRIAL

EHA Library, Mark-David Levin, 324557

LOSS OF G0/G1 SWITCH GENE 2 (G0S2) IN CML PROMOTES TKI RESISTANCE BY DEREGULATING THE MITOCHONDRIAL ELECTRON TRANSPORT CHAIN.

EHA Library, Mayra Gonzalez, 324558

MITOCHONDRIAL DNA MUTATIONS ARE ASSOCIATED WITH RESPONSE TO IMATINIB IN CHRONIC MYELOID LEUKAEMIA PATIENTS

EHA Library, Ilaria Pagani, 324559

FINAL ANALYSIS OF A PAN EUROPEAN STOP TYROSINE KINASE INHIBITOR TRIAL IN CHRONIC MYELOID LEUKEMIA : THE EURO-SKI STUDY

EHA Library, Susanne Saussele, 324560

OPTIC PRIMARY ANALYSIS: A DOSE-OPTIMIZATION STUDY OF 3 STARTING DOSES OF PONATINIB (PON)

EHA Library, Jorge Cortes, 324561

COVID-19 INFECTION IN CHRONIC MYELOID LEUKEMIA AFTER 1 YEAR OF THE PANDEMIC IN ITALY. A CAMPUS CML ANALYSIS

EHA Library, Massimo Breccia, 324562

THE LOSS OF LIFE EXPECTANCY IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA: A POPULATION-BASED STUDY IN THE NETHERLANDS, 1989-2018

EHA Library, Carolien Maas, 324563

ELTROMBOPAG FOR MYELODYSPLASTIC SYNDROMES OR CHRONIC MYELOMONOCYTIC LEUKEMIA WITH NO EXCESS BLASTS AND THROMBOCYTOPENIA: A FRENCH MULTICENTER RETROSPECTIVE REAL-LIFE STUDY.

EHA Library, Thibault Comont, 324564

EVALUATION OF THE IMPACT OF THE USE OF ELTROMBOPAG IN A REAL-LIFE SETTING IN FRANCE BASED ON DATA IN THE NATIONAL OBSERVATORY FOR MEDULLAR INSUFFICIENCY (RIME): THE REVEPI STUDY

EHA Library, Régis Peffault de Latour, 324565

IMPACT OF RUXOLITINIB ON SURVIVAL OF PATIENTS WITH MYELOFIBROSIS IN REAL WORLD – UPDATE OF ERNEST (EUROPEAN REGISTRY FOR MYELOPROLIFERATIVE NEOPLASMS) STUDY

EHA Library, Paola Guglielmelli, 324566

CLONAL HEMATOPOIESIS, ELEVATED BLOOD CELL COUNTS, AND DECREASED RENAL FUNCTION – A GENERAL POPULATION STUDY

EHA Library, Morten Kranker Larsen, 324567

CONCURRENT MUTATIONS IN ZRSR2 AND TET2 DISRUPT MYELOID AND ERYTHROID DIFFERENTIATION AND CAUSE ABNORMALITIES COMPATIBLE WITH MDS DISEASE IN MICE

EHA Library, Cristian Garcia-Ruiz, 324568

ACTIVATION OF DISTINCT INFLAMMATORY PATHWAYS IS DRIVEN BY GENETICS IN MDS

EHA Library, Marie Schneider, 324569

TET2 MUTATIONS IN MYELODYSPLASTIC SYNDROME PATIENTS DISRUPTS NATURAL KILLER CELL'S BIOLOGY

EHA Library, Maxime Boy, 324570

E-CADHERIN CONTROLS ERYTHROPOIESIS: A NOVEL AVENUE TO ANEMIA TREATMENT

EHA Library, Rosa Krimpenfort, 324571

RVU120/SEL120 CDK8/19 INHIBITOR - A DRUG CANDIDATE FOR THE TREATMENT OF MDS CAN INDUCE ERYTHROID DIFFERENTIATION IN TRANSFORMED CD34+ HEMATOPOIETIC PROGENITOR CELLS

EHA Library, Tomasz Rzymski, 324572

A PHASE 1, DOSE ESCALATION TRIAL WITH NOVEL ORAL IRAK4 INHIBITOR CA-4948 IN PATIENTS WITH ACUTE MYELOGENOUS LEUKEMIA OR MYELODYSPLASTIC SYNDROME – INTERIM REPORT

EHA Library, Guillermo Garcia-Manero, 324573

LOWER RESIDUAL MUTATION LOAD FOLLOWING TREATMENT WITH PEVONEDISTAT+AZACITIDINE VERSUS AZACITIDINE ALONE: COMPARATIVE ANALYSIS OF STUDY ARMS IN P-2001, A RANDOMIZED PHASE 2 TRIAL

EHA Library, Mikkael Sekeres, 324574

PHASE II STUDY OF THE IDH2-INHIBITOR ENASIDENIB IN PATIENTS WITH HIGH-RISK IDH2-MUTATED MYELODYSPLASTIC SYNDROMES (MDS)

EHA Library, Sangeetha Venugopal, 324575

SABATOLIMAB PLUS HYPOMETHYLATING AGENTS (HMAS) IN PATIENTS (PTS) WITH HIGH-/VERY HIGH-RISK MYELODYSPLASTIC SYNDROME (HR/VHR-MDS) AND ACUTE MYELOID LEUKEMIA (AML): SUBGROUP ANALYSIS OF A PHASE 1 STUDY

EHA Library, Andrew Wei, 324576

CLINICAL CHARACTERISTICS AND SURVIVAL OF GATA2-MUTATED MYELOID NEOPLASMS: SINGLE INSTITUTION EXPERIENCE

EHA Library, Ahmad Nanaa, 324577

GATA2 HAPLOINSUFFICIENCY REDUCES AGED HEMATOPOIETIC STEM CELL FUNCTIONALITY IN MULTIPLE LINEAGES

EHA Library, Cansu Koyunlar, 324578

GLYCOSYLPHOSPHATIDYLINOSITOL-ANCHORED PROTEIN DEFICIENCY CONFERS RESISTANCE TO ANTIGEN-SPECIFIC T CELLS ON HEMATOPOIETIC STEM PROGENITOR CELLS IN APLASTIC ANEMIA PATIENTS WITH HLA-DR15

EHA Library, Noriaki Tsuji, 324579

AN INTERVENTIONAL, PHASE 2, SINGLE-ARM STUDY TO ASSESS THE EFFICACY AND SAFETY OF ELTROMBOPAG COMBINED WITH CYCLOSPORINE AS FIRST-LINE THERAPY IN ADULTS WITH SEVERE ACQUIRED APLASTIC ANEMIA (SOAR)

EHA Library, Efreen Montano, 324580

FIRST-LINE TREATMENT OF PNH PATIENTS WITH IPTACOPAN LEADS TO RAPID AND DURABLE HEMOGLOBIN INCREASE BY CONTROLLING BOTH INTRA- AND EXTRAVASCULAR HEMOLYSIS

EHA Library, Jun Ho Jang, 324581

FORTY-EIGHT WEEK EFFICACY AND SAFETY OF PEGCETACOPLAN IN ADULT PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA AND SUBOPTIMAL RESPONSE TO PRIOR ECULIZUMAB TREATMENT

EHA Library, Régis Peffault de Latour, 324582

SINGLE AND DOUBLE HIT EVENTS IN GENES ENCODING FOR IMMUNOTHERAPY TARGETS IN MULTIPLE MYELOMA

EHA Library, Leo Rasche, 324583

DISCOVERY OF A SELECTIVE INHIBITOR OF THE SETD2 HISTONE METHYLTRANSFERASE WITH POTENT IN VITRO AND IN VIVO ACTIVITY IN PRECLINICAL MODELS OF MULTIPLE MYELOMA

EHA Library, Jennifer Totman, 324584

REGULATED MEMBRANE BOUND IL-15 INCREASES BCMA CAR-T EXPANSION, POTENCY, AND DURABILITY OF RESPONSE IN A XENOGRAFT MODEL OF MULTIPLE MYELOMA

EHA Library, Brian Dolinski, 324585

IMPROVING THE RISK STRATIFICATION OF MULTIPLE MYELOMA WITH A BASE EDITORS/INFLAMMATION-BASED SCORING SYSTEM

EHA Library, Afsanehsadat Mojtabanezhad Shariatpanahi, 324586

MULTIPLE MYELOMA DERIVED MITOCHONDRIAL DAMPS PROMOTE A PRO-INFLAMMATORY SIGNATURE WITHIN THE MYELOMA BONE MARROW MICROENVIRONMENT

EHA Library, Aisha Jibril, 324587

DARATUMUMAB MAINTENANCE VS OBSERVATION IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA TREATED WITH BORTEZOMIB, THALIDOMIDE, AND DEXAMETHASONE ± DARATUMUMAB AND ASCT: CASSIOPEIA PART 2 RESULTS

EHA Library, Philippe Moreau, 324588

DEPTH OF RESPONSE AND MRD STATUS IN ULTRA HIGH-RISK MYELOMA AND PLASMA CELL LEUKEMIA TREATED WITH DARA-CVRD AND AUGMENTED AUTOLOGOUS TRANSPLANT: RESULTS OF THE RISK-STRATIFIED UK OPTIMUM/MUKNINE TRIAL

EHA Library, Martin Kaiser, 324589

EFFICACY OF CARFILZOMIB-BASED INDUCTION/CONSOLIDATION WITH OR WITHOUT AUTOLOGOUS TRANSPLANT AND LENALIDOMIDE OR CARFILZOMIB-LENALIDOMIDE MAINTENANCE IN HIGH-RISK PATIENTS IN THE FORTE TRIAL

EHA Library, Roberto Mina, 324590

UPDATED INTERIM ANALYSIS OF THE GMMG-CONCEPT TRIAL INVESTIGATING ISATUXIMAB, CARFILZOMIB, LENALIDOMIDE, AND DEXAMETHASONE (ISA-KRD) IN FRONT-LINE TREATMENT OF HIGH-RISK MULTIPLE MYELOMA

EHA Library, Katja Weisel, 324591

MEASURABLE RESIDUAL DISEASE (MRD) EVALUATION DURING IXAZOMIB (IXA) MAINTENANCE IN NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM): A LARGE ANALYSIS OF 1280 PATIENTS (PTS) ENROLLED IN TOURMALINE-MM3 AND -MM4

EHA Library, Bruno Paiva, 324592

CIRCULATING TUMOR CELLS (CTC) ARE THE MOST RELEVANT DIAGNOSTIC BIOMARKER IN TRANSPLANT-ELIGIBLE MULTIPLE MYELOMA (MM)

EHA Library, Juan-José Garcés, 324593

UPDATES FROM ICARIA-MM, A PHASE 3 STUDY OF ISATUXIMAB (ISA) PLUS POMALIDOMIDE AND LOW-DOSE DEXAMETHASONE (PD) VERSUS PD IN RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM)

EHA Library, Aurore Perrot, 324594

IBERDOMIDE (IBER) IN COMBINATION WITH DEXAMETHASONE (DEX) AND DARATUMUMAB (DARA), BORTEZOMIB (BORT), OR CARFILZOMIB (CFZ) IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)

EHA Library, Sagar Lonial, 324595

ONCE WEEKLY SELINEXOR, CARFILZOMIB, AND DEXAMETHASONE (XKD) IN CARFILZOMIB NONREFRACTORY MULTIPLE MYELOMA (MM) PATIENTS

EHA Library, Cristina Gasparetto, 324596

UPDATED RESULTS FROM PHASE 3 ANDROMEDA STUDY OF PATIENTS WITH NEWLY DIAGNOSED LIGHT CHAIN AMYLOIDOSIS TREATED WITH BORTEZOMIB, CYCLOPHOSPHAMIDE, AND DEXAMETHASONE PLUS SUBCUTANEOUS DARATUMUMAB

EHA Library, Efstathios Kastritis, 324597

EFFICACY AND SAFETY OF THE BCMA-DIRECTED CAR-T CELL THERAPY, CILTACABTAGENE AUTOLEUCEL, IN PATIENTS WITH PROGRESSIVE MULTIPLE MYELOMA AFTER 1–3 PRIOR LINES OF THERAPY: INITIAL RESULTS FROM CARTITUDE-2

EHA Library, Mounzer Agha, 324598

TALQUETAMAB, A G PROTEIN-COUPLED RECEPTOR FAMILY C GROUP 5 MEMBER D (GPRC5D) × CD3 BISPECIFIC ANTIBODY, IN RELAPSED/REFRACTORY MULTIPLE MYELOMA: UPDATED RESULTS OF A PHASE 1, FIRST-IN-HUMAN STUDY

EHA Library, Amrita Y. Krishnan, 324599

MAGNETISMM-1: PHASE 1 STUDY OF ELRANATAMAB (PF-06863135), A B-CELL MATURATION ANTIGEN (BCMA) TARGETED CD3-ENGAGING BISPECIFIC ANTIBODY, FOR PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (MM)

EHA Library, Caitlin Costello, 324600

TECLISTAMAB, A B-CELL MATURATION ANTIGEN (BCMA) × CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: UPDATED PHASE 1 RESULTS

EHA Library, Niels W C J van de Donk, 324601

AN UPDATED PHASE 1 STUDY OF A NOVEL FULLY HUMAN BCMA-TARGETING CAR-T CELLS (CT103A) IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

EHA Library, Chunrui Li, 324602

INTERFERON-ALPHA TREATMENT RESULTS IN THE DEPLETION OF DORMANT JAK2-MUTANT HSC IN A MURINE MODEL OF POLYCYTHEMIA VERA

EHA Library, Jeyan Jayarajan, 324603

CALR FRAMESHIFT MUTATIONS ACCELERATE MATURATION OF MEGAKARYOCYTES IN MPN PATIENT-DERIVED IPS CELLS

EHA Library, Kathrin Olschok, 324604

TYK2 INHIBITION IS A NOVEL SELECTIVE THERAPEUTIC APPROACH FOR CALR- BUT NOT JAK2V617F-MUTANT MYELOPROLIFERATIVE NEOPLASMS

EHA Library, Rebecca Lemanzyk, 324605

IDENTIFICATION AND PHENOTYPIC CHARACTERIZATION OF DISEASE-INITIATING CD34+/CD38− STEM CELLS IN BCR-ABL1-NEGATIVE MYELOPROLIFERATIVE NEOPLASMS

EHA Library, Daniel Ivanov, 324606

BH3-MIMETICS AND AZACITIDINE SHOW SYNERGISTIC EFFECTS ON JUVENILE MYELOMONOCYTIC LEUKEMIA

EHA Library, Naile Koleci, 324607